EDAIC - European Diploma in Anesthesiology and Intensive Care Coagulation and Transfusion Medicine Questions and Answers — Questions and Answers
Question 1: A 78-year-old male on long-term apixaban for atrial fibrillation presents to the emergency department with a life-threatening gastrointestinal bleed. He requires urgent endoscopy. Which of the following is the most appropriate agent for the immediate reversal of apixaban's anticoagulant effect?
- Prothrombin Complex Concentrate (PCC)
- Vitamin K
- Andexanet alfa (Correct answer)
- Fresh Frozen Plasma (FFP)
Correct answer: Andexanet alfa
Andexanet alfa is a recombinant modified factor Xa protein that acts as a decoy, binding to and sequestering factor Xa inhibitors like apixaban and rivaroxaban. [2, 3] This action rapidly neutralizes their anticoagulant effect. [1, 12] PCC contains factors II, VII, IX, and X, and can be used off-label, but it is not a specific antidote. Vitamin K is used to reverse warfarin and has no effect on DOACs. FFP contains all clotting factors but is not concentrated, requires large volumes, and is not a first-line reversal agent for factor Xa inhibitors. [9, 22]
Question 2: A massively bleeding trauma patient has a critically low fibrinogen level of 0.7 g/L. Which blood product is the most concentrated source of fibrinogen and therefore the most appropriate choice to specifically correct this deficiency?
- Fresh Frozen Plasma (FFP)
- Cryoprecipitate (Correct answer)
- Platelet Concentrate
- Packed Red Blood Cells (PRBCs)
Correct answer: Cryoprecipitate
Cryoprecipitate is a plasma-derived product that is a concentrated source of fibrinogen, Factor VIII, von Willebrand factor, and Factor XIII. [5, 8, 15] It is the treatment of choice for significant hypofibrinogenemia (<1.0-1.5 g/L) as it provides a large amount of fibrinogen in a small volume. [7, 8, 14] While FFP contains fibrinogen, it is much less concentrated, requiring a larger volume to achieve the same effect. [4, 9] Platelets and PRBCs do not contain significant amounts of fibrinogen.
Question 3: Within two hours of receiving a transfusion of packed red blood cells, a 65-year-old ICU patient develops acute respiratory distress, hypoxemia (SpO2 85% on 60% O2), and bilateral infiltrates on chest X-ray. Her blood pressure is 90/50 mmHg, and there are no signs of fluid overload such as jugular venous distension or peripheral edema. Which of the following is the most likely diagnosis?
- Transfusion-Associated Circulatory Overload (TACO)
- Anaphylactic Reaction
- Acute Hemolytic Transfusion Reaction
- Transfusion-Related Acute Lung Injury (TRALI) (Correct answer)
Correct answer: Transfusion-Related Acute Lung Injury (TRALI)
The clinical picture of acute hypoxemia and bilateral pulmonary edema occurring within 6 hours of transfusion, in the absence of signs of circulatory overload (e.g., hypotension rather than hypertension), is characteristic of Transfusion-Related Acute Lung Injury (TRALI). [11, 23, 34] TRALI is a form of non-cardiogenic pulmonary edema. [10, 34] In contrast, Transfusion-Associated Circulatory Overload (TACO) is a cardiogenic or hydrostatic pulmonary edema, typically associated with signs of fluid overload like hypertension and elevated central venous pressure. [36, 42] Anaphylaxis often involves bronchospasm and urticaria, and an acute hemolytic reaction typically presents with fever, chills, hemoglobinuria, and flank pain.
Question 4: A bleeding patient's ROTEM analysis shows a normal EXTEM Clotting Time (CT), but the Maximum Clot Firmness (MCF) is severely reduced. The FIBTEM analysis also shows a severely reduced MCF. What is the most likely deficiency that needs to be addressed?
- Platelet dysfunction
- Fibrinogen deficiency (Correct answer)
- Coagulation factor deficiency
- Hyperfibrinolysis
Correct answer: Fibrinogen deficiency
In ROTEM, the Maximum Clot Firmness (MCF) reflects the overall strength of the clot, which is dependent on platelets and fibrinogen. The FIBTEM test uses cytochalasin D to inhibit platelets, thereby isolating the contribution of fibrinogen to clot strength. [31, 47] A severely reduced MCF on both the EXTEM and FIBTEM tests indicates that the primary problem is a deficiency in fibrinogen quantity or quality. [30, 46] A normal Clotting Time (CT) suggests that the initiation of coagulation (i.e., coagulation factor activity) is adequate.
Question 5: A 52-year-old patient with end-stage liver disease is actively bleeding. Laboratory results show INR 3.0, platelets 50 x 10^9/L, and fibrinogen 0.8 g/L. To establish a functional clot, which of the following should be prioritized for replacement?
- Cryoprecipitate or Fibrinogen Concentrate (Correct answer)
- Prothrombin Complex Concentrate (PCC)
- Platelets
- Fresh Frozen Plasma (FFP)
Correct answer: Cryoprecipitate or Fibrinogen Concentrate
In patients with end-stage liver disease, coagulopathy is complex, involving deficiencies in both pro- and anti-coagulants. [27, 43] However, fibrinogen is the essential substrate for clot formation. A level below 1.0-1.2 g/L is critically low and severely impairs the ability to form a stable clot, regardless of other factor levels. [18, 32] Therefore, correcting the severe hypofibrinogenemia with a concentrated source like cryoprecipitate or fibrinogen concentrate is the first priority. [20, 44] While platelets, FFP, and PCC may also be required, they cannot be effective without sufficient fibrinogen substrate.
Question 6: Which of the following statements best describes the primary mechanism of action of tranexamic acid (TXA) in a trauma patient with massive hemorrhage?
- It directly activates platelets to enhance primary hemostasis.
- It provides concentrated clotting factors to accelerate the coagulation cascade.
- It inhibits the conversion of fibrinogen to fibrin.
- It prevents the breakdown of existing clots by inhibiting plasminogen activation. (Correct answer)
Correct answer: It prevents the breakdown of existing clots by inhibiting plasminogen activation.
Tranexamic acid is a synthetic lysine analog. Its primary mechanism is antifibrinolytic. It competitively inhibits the activation of plasminogen to plasmin, the enzyme responsible for clot degradation (fibrinolysis). [28, 29] By preventing plasmin from binding to fibrin, it stabilizes formed clots and reduces bleeding, particularly in the context of trauma-induced coagulopathy where hyperfibrinolysis is common. [25, 33] It does not directly activate platelets, provide clotting factors, or inhibit fibrin formation.
EDAIC - European Diploma in Anesthesiology and Intensive Care Coagulation and Transfusion Medicine Questions and Answers
A 78-year-old male on long-term apixaban for atrial fibrillation presents to the emergency department with a life-threatening gastrointestinal bleed.
He requires urgent endoscopy.
Which of the following is the most appropriate agent for the immediate reversal of apixaban's anticoagulant effect?